anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Biologic agents, especially anti-TNFα treatments are widely used in inflammatory arthritis such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS). More than 60% of RA or AS patients achieve good clinical response to anti-TNFα treatment. However, TNFα is also an important mediator participating in the normal immune response to infectious agents, in particular intracellular microorganisms in the human body. Therefore, opportunistic infections such as tuberculosis, viral and fungal infections have been of concern when using anti-TNFα agents. With accumulating experience, the treatment guideline for anti-TNFα therapy in latent tuberculosis is now well established. It is noteworthy that there are a number of case reports describing hepatitis B virus (HBV) reactivation in otherwise asymptomatic carriers who received anti-TNFα treatment. Anti-TNFα agents are now utilized as a promising treatment regimen for RA and AS treatment for even HBsAg carriers, yet there are still concerns of the risk of anti-TNFα therapy contributing to HBV reactivation. In our previous studies, we found that anti-viral therapy before starting anti-TNFα treatment may reduce the incidence of HBV reactivation, and that entecavir is likely more suitable in long-term prophylaxis for HBsAg carriers under anti-TNFα treatment. This justifies the need of a prospective trial that could demonstrate the long-term effects of prophylaxis in using anti-TNFα therapy in this subgroup of patients. It would help clinicians understand 1) whether anti-viral therapy is necessary in inactive HBsAg carriers initiating anti-TNFα treatment, and 2) at what time point would we most likely witness HBV reactivation after starting anti-TNFα therapy without anti-viral therapy coverage. In addition to established nationwide network of Rheumatologists working in major academic institutes in Korea, our division in Seoul National University Hospital has led many multi-center trials throughout the past years. In summary, the question of whether to combine anti-viral prophylaxis in HBsAg carriers starting anti-TNFα therapy is an important issue to Rheumatologists. There is no guideline for managing this subset of patients, and clinicians normally begin anti-viral therapy after the patient's liver function worsens. Therefore, our nationwide network of specialists proposes to launch a prospective study to investigate the benefit of anti-viral prophylaxis with entecavir in HBsAg carriers starting anti-TNFα treatment.
PURPOSE: Dialysis patients are at an increased risk of developing renal cell carcinoma (RCC); however, differentiating between RCC and benign cysts can sometimes be difficult using modalities, such as computed tomography (CT) and ultrasonography. 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET)/CT efficiently detects malignant tumors; however, physiological accumulation of FDG in the kidney limits its efficacy in detecting renal tumors. However, in patients with severely impaired renal function, the renal accumulation of FDG is decreased, possibly improving the detection of renal malignancies in this patient population. This study evaluated the usefulness of FDG-PET/CT as a screening tool for detecting RCC in patients with end-stage renal disease.
MATERIALS AND METHODS: This prospective study recruited 150 participants from 2012 to 2016 who were on dialysis or underwent renal transplantation and were on dialysis until transplantation. FDG-PET/CT was performed to screen for RCC. Three radiologists independently evaluated the images. No protocol was defined for the additional management of positive examinations, leaving decisions to the discretion of each participant. Negative examinations were observed until the end of 2019.
RESULTS: In total, 150 participants (mean age, 58 ± 13 years; 105 men) underwent FDG-PET/CT. Twenty patients (13.4%) were diagnosed as positive. Fifteen patients underwent additional examinations and/or procedures, and RCC was found in seven patients. Of the four patients who underwent surgical resection, the pathological results were clear cell RCC in one, papillary RCC in one, and acquired cystic disease-associated RCC in two. Two participants were diagnosed with RCC on bone biopsy, and one was diagnosed on dynamic CT but opted for observation. The sensitivity, specificity, and negative predictive value were 100%, 93.9%, and 100%, respectively.
CONCLUSION: FDG-PET/CT was useful for detecting RCC in patients with end-stage renal disease. Our findings show the potential use of FDG-PET/CT as a screening tool for RCC in this patient population.
The present invention relates to a system and a method for controlling driving of an LED body irradiating device for treatment. The system for controlling driving of an LED body irradiating device for treatment comprises a user terminal, a managing server and a body irradiating device. When a desired mode and use time are selected from a user and costs are paid corresponding to selected information, the user terminal extracts a wavelength, a light amount, and frequency information corresponding to the selected mode by using a database and transmits the extracted information with the selected use time. The managing server receives the extracted information and the selected use time, generates a protocol by using the received information, and transmits the generated protocol with the selected use time. The body irradiating device receives the protocol and the selected use time, generates a driving signal for driving a plurality of LED bars during the selected use time by analyzing the received protocol, and drives each of the LED bars by using the generated driving signal. When the desired mode is selected from the user by connecting the user terminal for selection and payment of a desired mode, the present invention automatically sets the wavelength, the light amount, and the frequency of a corresponding light source and provides the same to the user. Therefore, the present invention can improve satisfaction of the user by providing easy use of a device.
PURPOSE: Variability in auditory-perceptual ratings of voice limits their utility, with the poorest reliability often noted for vocal strain. The purpose of this study was to determine whether an experimental method, called visual sort and rate (VSR), promoted stronger rater reliability than visual analog scale (VAS), for ratings of strain in two clinical populations: adductor laryngeal dystonia (ADLD) and vocal hyperfunction (VH).
METHOD: Connected speech samples from speakers with ADLD and VH as well as age- and sex-matched controls were selected from a database. Fifteen inexperienced listeners rated strain for two speaker sets (25 ADLD speakers and five controls; 25 VH speakers and five controls) across four rating blocks: VAS-ADLD, VSR-ADLD, VAS-VH, and VSR-VH. For the VAS task, listeners rated each speaker for strain using a vertically oriented 100-mm VAS. For the VSR task, stimuli were distributed into sets of samples with a range of severities in each set. Listeners sorted and ranked samples for strain within each set, and final ratings were captured on a vertically oriented 100-mm VAS. Intrarater reliability (Pearson's r) and interrater variability (mean of the squared differences between a listener's ratings and group mean ratings) were compared across rating methods and populations using two repeated-measures analyses of variance.
RESULTS: Intrarater reliability of strain was significantly stronger when listeners used VSR compared to VAS; listeners also showed significantly better intrarater reliability in ADLD than VH. Listeners demonstrated significantly less interrater variability (better reliability) when using VSR compared to VAS. No significant effect of population or interactions was found between listeners for measures of interrater variability.
CONCLUSIONS: VSR increases intrarater reliability for ratings of vocal strain in speakers with VH and ADLD. VSR decreases variability of auditory-perceptual judgments of strain between inexperienced listeners in these clinical populations. Future research should determine whether benefits of VSR extend to voice clinicians and/or clinical settings.
The efficacy and safety of tadalafil for once daily use for the treatment of ED, and the signs and symptoms of BPH, in patients with both conditions was evaluated in one placebo-controlled, multinational, double-blind, parallel-arm study which randomized 606 patients to receive either tadalafil 2.5 mg, 5 mg, for once daily use or placebo. ED severity ranged from mild to severe and BPH severity ranged from moderate to severe. The full study population had a mean age of 63 years (range 45 to 83) and was 93% White, 4% Black, 3% other races; 16% were of Hispanic ethnicity. Patients with multiple co-morbid conditions such as diabetes mellitus, hypertension, and other cardiovascular disease were included.

In this study, the co-primary endpoints were total IPSS and the Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF). One of the key secondary endpoints in this study was Question 3 of the Sexual Encounter Profile diary (SEP3). Timing of sexual activity was not restricted relative to when patients took tadalafil.

The efficacy results for patients with both ED and BPH, who received either tadalafil 5 mg for once daily use or placebo (N=408) are shown in Tables 21 and 22 and Figure 8.

Tadalafil 5 mg for once daily use resulted in statistically significant improvements in the total IPSS and in the EF domain of the IIEF questionnaire. Tadalafil 5 mg for once daily use also resulted in statistically significant improvement in SEP3. Tadalafil 2.5 mg did not result in statistically significant improvement in the total IPSS.

Tadalafil tablets for once daily use resulted in improvement in the IPSS total score at the first scheduled observation (week 2) and throughout the 12 weeks of treatment (see Figure 8).

Figure 8

Mean IPSS Changes in ED/BPH Patients by Visit in Study L

In this study, the effect of Tadalafil 5 mg once daily on Qmax was evaluated as a safety endpoint. Mean Qmax increased from baseline in both the treatment and placebo groups (Tadalafil 5 mg: 1.6 mL/sec, placebo: 1.2 mL/sec); however, these changes were not significantly different between groups.
Peyronie’s disease has been reported in fewer than 1 of 100,000 patients. Musculoskeletal pain, blurred vision, and tinnitus have also been reported.

There have been rare reports of reversible alopecia, agranulocytosis, and dry eyes. Discontinuation of the drug should be considered if any such reaction is not otherwise explicable. There have been very rare reports of weight gain, arthritis, and retroperitoneal fibrosis (relationship to metoprolol has not been definitely established).

The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with metoprolol.
Participants received 375 mg/m\^2 rituximab IV infusion once a week on Days 1, 8, 15 and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression were eligible to receive a 375 mg/m\^2 rituximab IV infusion once every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
There is no fixed dosage regimen for the management of diabetes mellitus with glyburide tablets. In addition to the usual monitoring of urinary glucose, the patient's blood glucose must also be monitored periodically to determine the minimum effective dose for the patient; to detect primary failure, i.e. , inadequate lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, i.e. , loss of adequate blood glucose lowering response after an initial period of effectiveness. Glycosylated hemoglobin levels may also be of value in monitoring the patient's response to therapy.

Short-term administration of glyburide tablets may be sufficient during periods of transient loss of control in patients usually controlled well on diet.
The home-based exergame intervention will take place in an unsupervised place of the participant's choosing. Participants will be provided with all of the equipment (including a television if required) and receive instructions on how to use the system. Participants will be provided with a stepped training plan with exergame session durations of 19 minutes (4x 3-minutes 45-seconds of exercise interspersed with 1 minute of rest) in weeks 1 and 2; 24-minutes (4x 5-minutes of exercise interspersed with 1 minute of rest) in week 3 and 4; and 30-minutes (5x 5-minutes of exercise interspersed with 1 minute of rest) in week 5 and 6. Sessions will be set at a vigorous intensity (≥80% heart rate maximum) and participants will be provided with individualised heart rate zones to achieve in line with heart rate maximum determined during a maximal exercise test in Visit 2. Participants will be asked to train 3 times per week.
It is intended to provide a drug for inhibiting estrogen-dependent diseases, prostaglandin D (PGD)-dependent gynecological diseases, immunological diseases, cancer and angiogenesis. Namely, a drug aiming at inhibiting at least one member selected from the group consisting of estrogen-dependent diseases, PGD-dependent gynecological diseases, immunological diseases, cancer and angiogenesis characterized by containing an ingredient inhibiting the activity of a histamine release factor (HRF). By inhibiting the HRF activity, the expression of genes of, for example, IL-1β receptor, 17β hydroxy steroid dehydrogenase (HSD), etc. is inhibited. Thus, the estrogen activity is inhibited and estrogen-dependent diseases can be prevented, treated or ameliorated thereby. As the above-described ingredient inhibiting the RHF activity, it is preferred to use artemisinin.
The experimental manipulation for this study is the frustration task. The frustration task is designed to elicit the emotional state of frustrative non-reward (FNR). During the task, participants are asked to use button press (left or right) to alternately press one of the two doors displayed on the monitor. The task has two non-frustration blocks (Block 1 and 2) and one frustration block (Block 3). During the non-frustration blocks, participants earn money for correct press on a fixed schedule. During the frustrative block, participants will not always receive reward for correct press.
The present invention is directed to the use of cyclopeptides capable of effectively coordinating elements of the lanthanide series, preferably metal ions such as gd3. Said cyclic units can self-assemble, giving rise to the formation of nanotubular structures magnetically marked. In this way, it is possible to carry out the preparation of nanotubes for their application as contracting agents for magnetic resonance imaging (mri). Due to the shape of their supramolecular aggregates they possess anisotropic magnetic properties with applications in the early detection of various cancers and atherosclerosis problems. Secondly, this patent is also directed to the synthesis of intermediates useful for obtaining cyclopeptides and metal chelating agents. (Machine-translation by Google Translate, not legally binding)
This randomized,double-blind, placebo-controlled study will enroll 36 men and women with a diagnosis of NAFLD orNASH. The study will be conducted over a period of approximately 28 wks and will include:a Screening Phase (Days -14to -1); a 24-week long Treatment Phase, during which patients will be randomly assigned to receive ARI-3037MO or placebo; an End-of-study Visit (ESV) scheduled 2 wks after the end of the Treatment Phase The Screening Phase will include 2 visits. Visit 1:There will be an initial assessment of a patient's eligibility for participation in the study. A complete medical history will be obtained and prospective study patients will undergo physical examinations and laboratory evaluations. For patients who have had a liver biopsy in the 6months prior to Visit 1, the histology findings, i.e., NAS, steatosis score and fibrosis score will be recorded. Visit 2:Approximately 1 week after Visit 1, and after the results of clinical laboratory screening test results have been reviewed by the Principal Investigator (PI), patients will be contacted to advise them of their eligibility to continue in the study. Eligible patients will undergo liver magnetic resonance imaging (MRI) to assess intrahepatic fat content. Treatment Phase Patients with MRI results showing intrahepatic fat content of ≥10% will be entered into the Treatment Phase of the study. The Treatment Phase will include 4 outpatient visits over a period of 24 weeks. Visit 3:Patients will be randomly assigned to receive ARI-3037MO or placebo on Day 1 of a 24-week long outpatient treatment period. Baseline assessments, including FibroTest®, FibroScan® and clinical laboratory tests, will be performed, and patients will take study drug twice daily. Visits 4, 5 and 6: During the Treatment Phase, patients will visit the study clinic at 4, 12 and 24 weeks (± 4 days) after Day 1 for evaluations and examinations and to collect study drug. Twenty-four weeks after the start of dosing, at the end of the Treatment Phase, patients will undergo a follow-up MRI and FibroScan† to assess change from baseline in intrahepatic fat content and liver fibrosis, respectively.

†If FibroScan equipment is available at the study site End-of-Study Visit Visit 7:An ESV will occur 2 weeks (± 4 days) after the end of the Treatment Phase.
<P>PROBLEM TO BE SOLVED: To develop a functional feed for prophylaxis and therapy of bovine articular diseases, absorbable with high efficiency at a low cost, and for further details, the functional feed containing an amorphized chitin for cattle.  <P>SOLUTION: The feed, a prophylactic and therapeutic agent for the articular diseases and an antiinflammatory agent comprise the amorphized chitin. The prophylactic and therapeutic agent for the articular diseases is a cartilage destruction inhibitor or a chondrogenesis promoter. The feed, prophylactic and therapeutic agent or antiinflammatory agent is produced by using the amorphized chitin. Furthermore, the amorphized chitin, feed and prophylactic and therapeutic agent for the articular diseases are used for the therapy or prophylaxis of the bovine articular diseases. The amorphous chitin, feed and antiinflammatory agent are used for the therapy or prophylaxis of bovine inflammations. A method for treating the bovine articular diseases comprises administering the amorphized chitin, feed and prophylactic and therapeutic agent for the articular diseases.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
Participants who pass all screening criteria will undergo a percutaneous procedure for the implantation of a permanent tricuspid repair device. Participants will be followed for 1 year to evaluate the safety and feasibility of the Versa System procedure and the Versa Tricuspid Repair Implant.
All patients will receive Telomelysin (OBP-301) at 2x10\^12 viral particles (VP)/ tumor injection administered every two weeks x 4 injections as well as standard dose pembrolizumab 200 mg IV every 3 weeks. The tumor will be injected with OBP-301 four times (d1, d15, d29, d43). The preference is to inject the primary tumor endoscopically. Metastatic lesions may be injected on a case-by-case basis after discussion with the PI (Shah).
The present disclosure relates to systems and processes for users of electronic devices to issue physical activity goal challenges and rewards to one another. In one example, a first user can provide a physical activity goal that is to be performed by a second user. The first user can further provide a reward that is to be given to the second user in response to the second user completing the physical activity goal. An electronic device associated with the second user can be used to detect physical activity performed by the second user and to determine whether the second user has completed the physical activity goal. In response to determining that the second user has completed the physical activity goal, the reward can be issued to the second user. The reward can include an image, video, song, electronic message, amount of virtual currency, access to a service, or the like.
Participants with severe renal impairment will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC. Severe renal impairment was defined as creatinine clearance \<30mL/min.
PURPOSE:To obtain oil-soluble vitamin powder useful as formula feed for fish breeding, etc., having excellent water-dispersing and solubilizing ability comprising specific two emulsifying agents as essential components by coating and powdering an oil-soluble vitamin with melted polyethylene glycol. CONSTITUTION:A polyoxyethylene sorbitan fatty acid ester to which <=10mol<30mol ethylene oxide is added and a polyoxyethylene sorbitan fatty acid ester to which <=30mol-<=50mol ethylene oxide is added are used as essential components for emulsifying agents and coated and powdered together with an oil-soluble vitamin (e. g. vitamin A or vitamin D) and melted polyethylene glycol. The blending ratio of the components is preferably >=10 pts.wt. emulsifying agents based on 90 pts.wt. oil-soluble vitamin to stably disperse the oil- soluble vitamin. The amount of the polyethylene glycol is preferably >=50 pts.wt. based on 50 pts.wt. total amounts of the emulsifying agents and the oil-soluble vitamin.
The invention relates to a preparation method of plural gel after-operation anti-adhesive material which contains calcium ion and carboxymethyl cellulose. The preparation method of the invention is to dissolve 0.5 to 5 grams of CMC in 95 to 99.5 grams of PBS buffer solution with pH value of 6.5 to 7.5, and is agitated fully to obtain even CMC solution; 0.01 to 8 grams of CaCl2 is added in the CMC solution and agitated fully, so as to obtain calcium ion CMC solution; 0.01 to 8 grams of Tranilast powder is added in the calcium ion CMC solution and agitated to be even, namely, the carboxymethyl cellulose gel with the medicine plus the calcium ion is obtained; the carboxymethyl cellulose gel is disinfected, and the finished product is obtained. Because CaCl2 is adopted, the security performance is good, and the product is harmless to the human body. An amount of CaCl2 is helpful to obtain the plural gel after-operation anti-adhesive material with favorable performance. The physical and the chemical performances can meet the requirements of after-operation anti-adhesion, and the anti-adhesive material is easy to adhere to the wound surface. The medicinal formula of the preparation method is simple, and the preparation process is easy to operate.
Patient will be shifted to operation theatre. Crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl. Each lower limb will be elevated alternately and wrapped from toe to mid-thigh with Esmarch bandage. Care will be taken to avoid compressing the legs to greater than arterial pressure by confirming the presence of pulse using a saturation probe. Following wrapping, the lower limbs will be brought to horizontal position. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol injected over 30 seconds. Muscle relaxation by inj. vecuronium. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube. Esmarch bandage will be removed 10 minutes after intubation.